irinotecan has been researched along with 1-octanol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awazu, S; Hosokawa, Y; Kaneda, N; Yokokura, T | 1 |
| Chen, J; Cheng, D; Deng, L; Ma, J; Wu, C; Yang, D; Zhang, J; Zhang, Y | 1 |
2 other study(ies) available for irinotecan and 1-octanol
| Article | Year |
|---|---|
Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Topics: 1-Octanol; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Buffers; Camptothecin; Drug Interactions; Injections, Intravenous; Irinotecan; Male; Rats; Rats, Wistar | 1997 |
Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study.
Topics: 1-Octanol; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Delivery Systems; Humans; Irinotecan; Liposomes; Mice; Neoplasms; Particle Size; Prodrugs; Solubility; Static Electricity; Tissue Distribution; Water | 2019 |